Patterns of use of insulin-sensitizing agents among diabetic, borderline diabetic and non-diabetic women in the National Health and Nutrition Examination Surveys

References

• Bhatia V, Viswanathan P. Insulin resistance and PPAR insulin sensitizers. Curr Opin Investig Drugs 2006;7:891–7
   PubMedGoogle Scholar
• Cho N, Momose Y. Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress. Curr Top Med Chem 2008;8:1483–507
   PubMed Web of Science ®Google Scholar
• Colca JR. Future directions for insulin sensitizers in disease prevention. Curr Opin Investig Drugs 2007;8:707–10
   PubMedGoogle Scholar
• Jawa A, Fonseca V. Cardiovascular effects of insulin sensitizers in diabetes. Curr Opin Investig Drugs 2006;7:806–14
   PubMedGoogle Scholar
• Norman RJ, Homan G, Moran L, Noakes M. Lifestyle choices, diet, and insulin sensitizers in polycystic ovary syndrome. Endocrine 2006;30:35–43
   PubMedGoogle Scholar
• Stein LL, Dong MH, Loomba R. Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: current status. Adv Ther 2009;26:893–907
   PubMed Web of Science ®Google Scholar
• Campbell RK, White JR, Jr Saulie BA. Metformin: a new oral biguanide. Clin Ther 1996;18:360–71; discussion 359
   PubMed Web of Science ®Google Scholar
• Mehnert H. Metformin, the rebirth of a biguanide: mechanism of action and place in the prevention and treatment of insulin resistance. Exp Clin Endocrinol Diabetes 2001;109:S259–64
   PubMedGoogle Scholar
• Berstein LM. Modern approach to metabolic rehabilitation of cancer patients: biguanides (phenformin and metformin) and beyond. Future Oncol 2010;6:1313–23
   PubMedGoogle Scholar
• Kwong SC, Brubacher J. Phenformin and lactic acidosis: a case report and review. J Emerg Med 1998;16:881–6
   PubMedGoogle Scholar
• Matsuura T, Miyao M, Mizuno Y. A case of lactic acidosis caused by buformin in an oldest elderly diabetic patient. Nihon Ronen Igakkai Zasshi 2005;42:235–40
   PubMedGoogle Scholar
• Stewart MW, Cirkel DT, Furuseth K, et al. Effect of metformin plus roziglitazone compared with metformin alone on glycaemic control in well-controlled Type 2 diabetes. Diabet Med 2006;23:1069–78
   PubMed Web of Science ®Google Scholar
• de Pablos-Velasco P. Pioglitazone: beyond glucose control. Expert Rev Cardiovasc Ther 2010;8:1057–67
   PubMedGoogle Scholar
• Derosa G. Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents. Drugs 2010;70:1945–61
   PubMed Web of Science ®Google Scholar
• Shah P, Mudaliar S. Pioglitazone: side effect and safety profile. Expert Opin Drug Saf 2010;9:347–54
   PubMed Web of Science ®Google Scholar
• Fujiwara T, Horikoshi H. Troglitazone and related compounds: therapeutic potential beyond diabetes. Life Sci 2000;67:2405–16
   PubMed Web of Science ®Google Scholar
• Parker JC. Troglitazone: the discovery and development of a novel therapy for the treatment of type 2 diabetes mellitus. Adv Drug Deliv Rev 2002;54:1173–97
   PubMed Web of Science ®Google Scholar
• Sangraula H, Paudel KR, Sharma M. Metformin and troglitazone in the treatment of female infertility associated with polycystic ovarian syndrome. JNMA J Nepal Med Assoc 2009;48:335–9
   PubMedGoogle Scholar
• Yokoi T. Troglitazone. Handb Exp Pharmacol 2010;196:419–35
   PubMedGoogle Scholar
• Vasisht KP, Chen SC, Peng Y, Bakris GL. Limitations of metformin use in patients with kidney disease: are they warranted? Diabetes Obes Metab 2010;12:1079–83
   PubMed Web of Science ®Google Scholar
• Bonow RO, Eckel RH. Diet, obesity, and cardiovascular risk. N Eng J Med 2003:348:2057–8
   PubMed Web of Science ®Google Scholar
• Stadtmauer LA, Wong BC, Oehninger S. Should patients with polycystic ovary syndrome be treated with metformin? Benefits of insulin sensitizing drugs in polycystic ovary syndrome beyond ovulation induction. Hum Reprod 2002;17:3016–26
   PubMed Web of Science ®Google Scholar
• Lacher DA, Thompson TD, Hughes JP, Saraiya M. Total, free, and percent free prostate-specific antigen levels among U.S. men, 2001–04. Adv Data 2006;379:1–12
   Google Scholar
• Joseph DA, Thompson T, Saraiya M, Werny DM. Association between glomerular filtration rate, free, total, and percent free prostate-specific antigen. Urology 2010;76:1042–6
   PubMed Web of Science ®Google Scholar
• Mondul AM, Selvin E, De Marzo AM, et al. Statin drugs, serum cholesterol, and prostate-specific antigen in the National Health and Nutrition Examination Survey 2001–2004. Cancer Causes Control 2010;21:671–8
   PubMed Web of Science ®Google Scholar